Skip to main content
Close up of a hand using a tablet

Latest News

Health Canada Approves of DENOZA™, a Denosumab Biosimilar

May 5, 2026

Apotex Inc., a Canadian based global pharmaceutical company announced that Health Canada has approved DENOZA™ (denosumab injection), a denosumab biosimilar, for its authorized indications.

These include the treatment of postmenopausal women with osteoporosis at high risk for fracture and the treatment of osteoporosis in men at high risk for fracture. DENOZA is also authorized for the remaining indications of the reference biologic.

To read the full announcement visit https://www.apotex.com/global/news/news-release/2026/04/07/apotex-strengthens-osteoporosis-care-in-canada-with-health-canada-s-approval-of-denoza-a-denosumab-biosimilar


OC MAKES THE NEWS – RECENT ITEMS

DENOZA® is now available in Canada

September 25, 2026

Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]

Healthcare Professional Educational Events

August 19, 2026

Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]

Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones

July 7, 2026

Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]

© Osteoporosis Canada, 2026
Charitable Registration No. 89551 0931 RR 0001